Cargando…

Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study

AIM: To investigate the safety and efficacy of S-1 plus oxaliplatin (SOX) as an adjuvant chemotherapy regimen in gastric cancer (GC) after D2 dissection. METHODS: GC Patients who underwent D2 gastrectomy from September 2009 to December 2011 in four Chinese institutions were enrolled. Patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Deng-Feng, Zheng, Fang-Chao, Zhao, Jun-Hui, Shen, Guo-Shuang, Ahmad, Raees, Zhang, Shui-Sheng, Zhang, Yu, Kan, Jie, Dong, Li, Wang, Zi-Yi, Zhao, Fu-Xing, Zhao, Jiu-Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163137/
https://www.ncbi.nlm.nih.gov/pubmed/30283800
http://dx.doi.org/10.12998/wjcc.v6.i10.373
_version_ 1783359288837668864
author Ren, Deng-Feng
Zheng, Fang-Chao
Zhao, Jun-Hui
Shen, Guo-Shuang
Ahmad, Raees
Zhang, Shui-Sheng
Zhang, Yu
Kan, Jie
Dong, Li
Wang, Zi-Yi
Zhao, Fu-Xing
Zhao, Jiu-Da
author_facet Ren, Deng-Feng
Zheng, Fang-Chao
Zhao, Jun-Hui
Shen, Guo-Shuang
Ahmad, Raees
Zhang, Shui-Sheng
Zhang, Yu
Kan, Jie
Dong, Li
Wang, Zi-Yi
Zhao, Fu-Xing
Zhao, Jiu-Da
author_sort Ren, Deng-Feng
collection PubMed
description AIM: To investigate the safety and efficacy of S-1 plus oxaliplatin (SOX) as an adjuvant chemotherapy regimen in gastric cancer (GC) after D2 dissection. METHODS: GC Patients who underwent D2 gastrectomy from September 2009 to December 2011 in four Chinese institutions were enrolled. Patients with stage IB-IIIC GC, who received adjuvant SOX treatment were matched by propensity scores with those who underwent surgery alone and those who conducted capecitabine plus oxaliplatin (XELOX) regimen. Disease-free survival (DFS) and overall survival (OS) were compared among the groups. In addition, adverse events in SOX patients were analyzed. RESULTS: Of 1944 GC patients who underwent D2 dissection, 867 were included for analysis. One hundred and seventeen patients treated with SOX were matched to 234 patients who conducted surgery alone. Fifty-seven patients treated with SOX were matched to 57 patients who received XELOX. The estimated five-year DFS was 57.5% in the adjuvant SOX group which was higher than that (44.6%) in the surgery alone group (P = 0.001); and the estimated five-year OS was 68.3% which was higher than that (45.8%) of surgery alone group (P < 0.001). Survival benefit was also revealed in stage III and > 60 years old subgroups (P < 0.001 and P = 0.015, respectively). Compared with XELOX regimen, SOX showed no significant difference in DFS (P = 0.340) and OS (P = 0.361). The most common ≥ 3 grade adverse events of SOX regimen were neutropenia (22.6%), leukopenia (8.9%) and thrombocytopenia (5.6%). CONCLUSION: Compared with surgery alone, SOX regimen significantly improves the long-term survival and has acceptable toxicity in patients with stage IB-IIIC GC after D2 dissection. It may be a novel adjuvant chemotherapy regimen in GC patients.
format Online
Article
Text
id pubmed-6163137
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-61631372018-10-03 Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study Ren, Deng-Feng Zheng, Fang-Chao Zhao, Jun-Hui Shen, Guo-Shuang Ahmad, Raees Zhang, Shui-Sheng Zhang, Yu Kan, Jie Dong, Li Wang, Zi-Yi Zhao, Fu-Xing Zhao, Jiu-Da World J Clin Cases Retrospective Study AIM: To investigate the safety and efficacy of S-1 plus oxaliplatin (SOX) as an adjuvant chemotherapy regimen in gastric cancer (GC) after D2 dissection. METHODS: GC Patients who underwent D2 gastrectomy from September 2009 to December 2011 in four Chinese institutions were enrolled. Patients with stage IB-IIIC GC, who received adjuvant SOX treatment were matched by propensity scores with those who underwent surgery alone and those who conducted capecitabine plus oxaliplatin (XELOX) regimen. Disease-free survival (DFS) and overall survival (OS) were compared among the groups. In addition, adverse events in SOX patients were analyzed. RESULTS: Of 1944 GC patients who underwent D2 dissection, 867 were included for analysis. One hundred and seventeen patients treated with SOX were matched to 234 patients who conducted surgery alone. Fifty-seven patients treated with SOX were matched to 57 patients who received XELOX. The estimated five-year DFS was 57.5% in the adjuvant SOX group which was higher than that (44.6%) in the surgery alone group (P = 0.001); and the estimated five-year OS was 68.3% which was higher than that (45.8%) of surgery alone group (P < 0.001). Survival benefit was also revealed in stage III and > 60 years old subgroups (P < 0.001 and P = 0.015, respectively). Compared with XELOX regimen, SOX showed no significant difference in DFS (P = 0.340) and OS (P = 0.361). The most common ≥ 3 grade adverse events of SOX regimen were neutropenia (22.6%), leukopenia (8.9%) and thrombocytopenia (5.6%). CONCLUSION: Compared with surgery alone, SOX regimen significantly improves the long-term survival and has acceptable toxicity in patients with stage IB-IIIC GC after D2 dissection. It may be a novel adjuvant chemotherapy regimen in GC patients. Baishideng Publishing Group Inc 2018-09-26 2018-09-26 /pmc/articles/PMC6163137/ /pubmed/30283800 http://dx.doi.org/10.12998/wjcc.v6.i10.373 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Ren, Deng-Feng
Zheng, Fang-Chao
Zhao, Jun-Hui
Shen, Guo-Shuang
Ahmad, Raees
Zhang, Shui-Sheng
Zhang, Yu
Kan, Jie
Dong, Li
Wang, Zi-Yi
Zhao, Fu-Xing
Zhao, Jiu-Da
Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
title Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
title_full Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
title_fullStr Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
title_full_unstemmed Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
title_short Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
title_sort adjuvant chemotherapy with s-1 plus oxaliplatin improves survival of patients with gastric cancer after d2 gastrectomy: a multicenter propensity score-matched study
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163137/
https://www.ncbi.nlm.nih.gov/pubmed/30283800
http://dx.doi.org/10.12998/wjcc.v6.i10.373
work_keys_str_mv AT rendengfeng adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT zhengfangchao adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT zhaojunhui adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT shenguoshuang adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT ahmadraees adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT zhangshuisheng adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT zhangyu adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT kanjie adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT dongli adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT wangziyi adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT zhaofuxing adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy
AT zhaojiuda adjuvantchemotherapywiths1plusoxaliplatinimprovessurvivalofpatientswithgastriccancerafterd2gastrectomyamulticenterpropensityscorematchedstudy